Payment overview · 2025
General Payments
$61.89
3 reported records · 3 companies
Healthcare provider profile · identity verified
David James Kyle, D.O.
Allopathic & Osteopathic Physicians|General Practice · LOS ANGELES, CA · NPI 1952531758
Verified facts
What the public records show
CMS Open Payments records show David James Kyle, D.O. received $61.89 in general payments during 2025 across 3 reported records.
Lilly USA, LLC accounted for 38.1% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 6 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Mounjaro.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 82 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 13 claims for Mounjaro by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $23.60 | 38.1% | 1 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $20.39 | 33.0% | 1 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $17.90 | 28.9% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $61.89 | 3 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $23.60 | 1 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $23.60 | 1 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $20.39 | 1 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $20.39 | 1 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $17.90 | 1 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $17.90 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| MOUNJARO mounjaro |
2025 | Mounjaro | 2024 | 13 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
82 | 23 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
13 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 1022 | 155 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 483 | 105 |
| Gabapentin | Gabapentin | 471 | 102 |
| Amlodipine Besylate | Amlodipine Besylate | 363 | 103 |
| Atorvastatin Calcium | Atorvastatin Calcium | 363 | 100 |
| Hydrochlorothiazide | Hydrochlorothiazide | 310 | 79 |
| Lisinopril | Lisinopril | 298 | 81 |
| Losartan Potassium | Losartan Potassium | 287 | 70 |
| Ibuprofen | Ibuprofen | 280 | 64 |
| Alprazolam | Alprazolam | 251 | 26 |
| Omeprazole | Omeprazole | 238 | 60 |
| Metformin Hcl | Metformin Hcl | 217 | 66 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 206 | 33 |
| Baclofen | Baclofen | 191 | 44 |
| Oxycodone Hcl | Oxycodone Hcl | 181 | 23 |
| Zolpidem Tartrate | Zolpidem Tartrate | 179 | 24 |
| Furosemide | Furosemide | 167 | 47 |
| Ozempic | Semaglutide | 166 | 28 |
| Trazodone Hcl | Trazodone Hcl | 158 | 35 |
| Diazepam | Diazepam | 151 | 24 |
| Promethazine Hcl | Promethazine Hcl | 142 | 17 |
| Pantoprazole Sodium | Pantoprazole Sodium | 130 | 40 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 127 | 30 |
| Fluticasone Propionate | Fluticasone Propionate | 127 | 38 |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 126 | 33 |
| Ondansetron Odt | Ondansetron | 126 | 34 |
| Simvastatin | Simvastatin | 125 | 38 |
| Levothyroxine Sodium | Levothyroxine Sodium | 121 | 34 |
| Tamsulosin Hcl | Tamsulosin Hcl | 118 | 32 |
| Metoprolol Succinate | Metoprolol Succinate | 116 | 37 |
| Lorazepam | Lorazepam | 114 | 17 |
| Diclofenac Sodium | Diclofenac Sodium | 111 | 32 |
| Montelukast Sodium | Montelukast Sodium | 110 | 26 |
| Atenolol | Atenolol | 83 | 18 |
| Buspirone Hcl | Buspirone Hcl | 83 | 18 |
| Jardiance | Empagliflozin | 82 | 23 |
| Metoprolol Tartrate | Metoprolol Tartrate | 80 | 24 |
| Clonidine Hcl | Clonidine Hcl | 79 | 22 |
| Ventolin Hfa | Albuterol Sulfate | 79 | 18 |
| Clonazepam | Clonazepam | 78 | 13 |
| Famotidine | Famotidine | 75 | 21 |
| Morphine Sulfate Er | Morphine Sulfate | 75 | 13 |
| Potassium Chloride | Potassium Chloride | 72 | 24 |
| Carvedilol | Carvedilol | 68 | 20 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 66 | 18 |
| Fluconazole | Fluconazole | 64 | 24 |
| Januvia | Sitagliptin Phosphate | 64 | 15 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 64 | 17 |
| Spironolactone | Spironolactone | 64 | 13 |
| Ondansetron Hcl | Ondansetron Hcl | 62 | 15 |
| Pioglitazone Hcl | Pioglitazone Hcl | 62 | 13 |
| Eliquis | Apixaban | 60 | 16 |
| Sertraline Hcl | Sertraline Hcl | 60 | 16 |
| Hydrocortisone | Hydrocortisone | 59 | 15 |
| Tramadol Hcl | Tramadol Hcl | 59 | 16 |
| Methocarbamol | Methocarbamol | 57 | 13 |
| Azelastine Hcl | Azelastine Hcl | 54 | 13 |
| Sumatriptan Succinate | Sumatriptan Succinate | 54 | 14 |
| Clopidogrel | Clopidogrel Bisulfate | 52 | 15 |
| Escitalopram Oxalate | Escitalopram Oxalate | 51 | suppressed |
| Meloxicam | Meloxicam | 49 | 14 |
| Naproxen | Naproxen | 49 | 13 |
| Pregabalin | Pregabalin | 49 | 16 |
| Amitriptyline Hcl | Amitriptyline Hcl | 45 | suppressed |
| Breyna | Budesonide/Formoterol Fumarate | 45 | 18 |
| Budesonide-Formoterol Fumarate | Budesonide/Formoterol Fumarate | 45 | 16 |
| Quetiapine Fumarate | Quetiapine Fumarate | 45 | suppressed |
| Xtampza Er | Oxycodone Myristate | 45 | suppressed |
| Allopurinol | Allopurinol | 44 | 12 |
| Nurtec Odt | Rimegepant Sulfate | 44 | suppressed |
| Tizanidine Hcl | Tizanidine Hcl | 43 | suppressed |
| Duloxetine Hcl | Duloxetine Hcl | 42 | suppressed |
| Doxepin Hcl | Doxepin Hcl | 41 | suppressed |
| Celecoxib | Celecoxib | 40 | suppressed |
| Methadone Hcl | Methadone Hcl | 40 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 40 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 40 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 39 | suppressed |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 39 | 11 |
| Metformin Hcl Er | Metformin Hcl | 37 | suppressed |
| Dextroamphetamine-Amphetamine | Dextroamphetamine/Amphetamine | 35 | suppressed |
| Levetiracetam | Levetiracetam | 35 | suppressed |
| Myrbetriq | Mirabegron | 35 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 35 | 19 |
| Loperamide | Loperamide Hcl | 34 | suppressed |
| Acyclovir | Acyclovir | 33 | suppressed |
| Colchicine | Colchicine | 33 | suppressed |
| Ezetimibe-Simvastatin | Ezetimibe/Simvastatin | 33 | suppressed |
| Lidocaine | Lidocaine | 33 | suppressed |
| Prednisone | Prednisone | 33 | 19 |
| Amoxicillin | Amoxicillin | 32 | 20 |
| Nystatin | Nystatin | 32 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 31 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 29 | 11 |
| Dicyclomine Hcl | Dicyclomine Hcl | 29 | suppressed |
| Methylprednisolone | Methylprednisolone | 29 | 21 |
| Nitrofurantoin | Nitrofurantoin Macrocrystal | 29 | 11 |
| Aripiprazole | Aripiprazole | 28 | suppressed |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 27 | suppressed |
| Benztropine Mesylate | Benztropine Mesylate | 27 | suppressed |
| Bumetanide | Bumetanide | 27 | suppressed |
| Dexlansoprazole Dr | Dexlansoprazole | 27 | suppressed |
| Oxycontin | Oxycodone Hcl | 27 | suppressed |
| Zolpidem Tartrate Er | Zolpidem Tartrate | 27 | suppressed |
| Citalopram Hbr | Citalopram Hydrobromide | 26 | suppressed |
| Comfort Ez Pen Needle | Pen Needle, Diabetic | 26 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 26 | suppressed |
| Alendronate Sodium | Alendronate Sodium | 23 | suppressed |
| Clotrimazole | Clotrimazole | 23 | suppressed |
| Ketoconazole | Ketoconazole | 23 | suppressed |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 22 | suppressed |
| Varenicline Tartrate | Varenicline Tartrate | 22 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 21 | suppressed |
| Megestrol Acetate | Megestrol Acetate | 21 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 21 | suppressed |
| Advair Diskus | Fluticasone Propion/Salmeterol | 20 | suppressed |
| Clonidine | Clonidine | 20 | suppressed |
| Estradiol | Estradiol | 20 | suppressed |
| Ezetimibe | Ezetimibe | 20 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 20 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 20 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 20 | suppressed |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 19 | suppressed |
| Glimepiride | Glimepiride | 19 | suppressed |
| Glipizide | Glipizide | 19 | suppressed |
| Hydromorphone Hcl | Hydromorphone Hcl | 19 | suppressed |
| Olanzapine | Olanzapine | 19 | suppressed |
| Xarelto | Rivaroxaban | 19 | suppressed |
| Fenofibrate | Fenofibrate | 18 | suppressed |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 18 | suppressed |
| Modafinil | Modafinil | 18 | suppressed |
| Spiriva Respimat | Tiotropium Bromide | 18 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 17 | suppressed |
| Lactulose | Lactulose | 17 | suppressed |
| Latanoprost | Latanoprost | 17 | suppressed |
| Nifedipine Er | Nifedipine | 17 | suppressed |
| Nitroglycerin | Nitroglycerin | 17 | suppressed |
| Promethazine-Dm | Promethazine/Dextromethorphan | 17 | suppressed |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 17 | suppressed |
| Sucralfate | Sucralfate | 17 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 17 | 15 |
| Bupropion Xl | Bupropion Hcl | 16 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 16 | suppressed |
| Risperidone | Risperidone | 16 | suppressed |
| Temazepam | Temazepam | 16 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 15 | suppressed |
| Opzelura | Ruxolitinib Phosphate | 15 | suppressed |
| Techlite Pen Needle | Pen Needle, Diabetic | 15 | suppressed |
| Chlorthalidone | Chlorthalidone | 14 | suppressed |
| Finasteride | Finasteride | 14 | suppressed |
| Mirtazapine | Mirtazapine | 14 | suppressed |
| Tradjenta | Linagliptin | 14 | suppressed |
| Digoxin | Digoxin | 13 | suppressed |
| Mounjaro | Tirzepatide | 13 | suppressed |
| Omega-3 Acid Ethyl Esters | Omega-3 Acid Ethyl Esters | 13 | suppressed |
| Phenytek | Phenytoin Sodium Extended | 13 | suppressed |
| Qvar Redihaler | Beclomethasone Dipropionate | 13 | suppressed |
| Testosterone Cypionate | Testosterone Cypionate | 13 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 13 | suppressed |
| Vemlidy | Tenofovir Alafenamide | 13 | suppressed |
| Alcohol Prep Pads | Alcohol Antiseptic Pads | 12 | suppressed |
| Cephalexin | Cephalexin | 12 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 12 | suppressed |
| Rivastigmine | Rivastigmine Tartrate | 12 | suppressed |
| Zaleplon | Zaleplon | 12 | suppressed |
| Butalbital-Acetaminophen-Caffe | Butalb/Acetaminophen/Caffeine | 11 | suppressed |
| Captopril | Captopril | 11 | suppressed |
| Diclofenac Sodium-Misoprostol | Diclofenac Sodium/Misoprostol | 11 | suppressed |
| Divalproex Sodium | Divalproex Sodium | 11 | suppressed |
| Entresto | Sacubitril/Valsartan | 11 | suppressed |
| Labetalol Hcl | Labetalol Hcl | 11 | suppressed |
| Movantik | Naloxegol Oxalate | 11 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 11 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $61.89 · 3 records | Lilly USA, LLC | MOUNJARO, OTEZLA, QULIPTA, REPATHA, UBRELVY, ZEPBOUND | 2 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Mounjaro play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with Lilly USA, LLC?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error